2012
MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions
Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. Sarcoma 2012, 2012: 404810. PMID: 22577336, PMCID: PMC3345255, DOI: 10.1155/2012/404810.Peer-Reviewed Original ResearchBone sarcomasClinical trialsEwing's sarcomaLimb salvage surgeryCurrent therapeutic modalitiesRecent clinical trialsMAPK/ERK inhibitorsPromising therapeutic targetHigh-grade chondrosarcomaCytotoxic chemotherapeutic drugsMAPK/ERK signalingSalvage surgeryTherapy regimensClinical benefitMetastatic osteosarcomaInflammatory responseMAPK/ERKClinical dataLocal invasivenessTherapeutic modalitiesCurrent chemotherapyTherapeutic conceptsTherapeutic implicationsTherapeutic targetSarcoma
2009
Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis
Seo SW, Lee D, Minematsu H, Kim AD, Shin M, Cho SK, Kim DW, Yang J, Lee FY. Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis. Bone 2009, 46: 695-702. PMID: 19895919, PMCID: PMC2823832, DOI: 10.1016/j.bone.2009.10.032.Peer-Reviewed Original ResearchConceptsInflammatory osteolysisInflammatory responseInnate immune responseExtracellular signal-regulated kinase (ERK) signalingImportant therapeutic targetM-CSF expressionSignal-regulated kinase 1/2 pathwaySignal-regulated kinase signalingExtracellular signal-regulated kinase 1/2 (ERK1/2) pathwayInhibition of ERKImmune responseTherapeutic implicationsTherapeutic targetOsteoclast precursorsKinase 1/2 pathwayM-CSFOsteolysisERK pathwayMacrophage colonyLPSERKERK signalsMitogen-activated protein kinase (MAPK) familyKinase signalingCell differentiation